Should I Buy RBOT? RBOT 2026 Analysis

Should You Buy Vicarious Surgical Inc (RBOT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.080

1 Day change

-2.35%

52 Week Range

16.350

Analysis Updated At

2026/01/26

Vicarious Surgical Inc (RBOT) is not a strong buy for a beginner, long-term investor at this time. The stock lacks clear positive catalysts, has weak financial performance, and no significant trading signals or analyst support. Given the user's preference for long-term investments, it would be prudent to wait for stronger financial growth trends or positive sentiment before considering an entry.

Technical Analysis

The MACD is slightly positive at 0.0301, indicating mild bullish momentum, but it is contracting. RSI is neutral at 44.638, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 2.433), but there is no strong indication of a breakout or reversal.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

NULL identified. No recent news, no significant insider or hedge fund activity, and no recent congress trading data.

Neutral/Negative Catalysts

Weak financial performance in Q3 2025 with a significant YoY decline in net income (-35.30%) and EPS (-35.86%). The stock also has a 70% chance of a slight decline (-1.17%) in the next day.

Financial Performance

The company's Q3 2025 financials show no revenue growth (0% YoY), a net income decline to -$11.058M (-35.30% YoY), and a drop in EPS to -1.86 (-35.86% YoY). Gross margin remains at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on recent analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast RBOT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RBOT is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 2.130

Low

Averages

High

Current: 2.130

Low

Averages

High

Piper Sandler

Neutral

downgrade

AI Analysis

2025-08-13

Reason

Piper Sandler

Price Target

AI Analysis

2025-08-13

downgrade

Neutral

Reason

Piper Sandler lowered the firm's price target on Vicarious Surgical to $7 from $8.50 and keeps a Neutral rating on the shares following quarterly results. Most notably, the company removed its goal for first clinical use by year-end and instead is focused on completing a fully integrated, production-equivalent system enabling design lock and initiating full system V&V, the firm says.

Piper Sandler

Adam Maeder

Hold

Maintains

$11 → $8.5

2025-03-18

Reason

Piper Sandler

Adam Maeder

Price Target

$11 → $8.5

2025-03-18

Maintains

Hold

Reason

Piper Sandler lowered the firm's price target on Vicarious Surgical to $8.50 from $10.50 and keeps a Neutral rating on the shares following quarterly results. Looking ahead to 2025, the company announced full year 2025 cash burn guidance of about $50M. The company also announced that it successfully completed the V1.0 system integration in Q4: 2024, which is an encouraging milestone in Piper's view. However, the company did note some minor supply chain issues related to component suppliers that now positions first-in-human cases to take place in late 2025.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RBOT

Unlock Now

RBOT Should I Buy

RBOT Should I Buy

Should You Buy Vicarious Surgical Inc (RBOT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch